TNFSF10 and cancer: Although the existing evidence is sufficient to inspire the investigation of TRAIL-related interventions (TRAIL gene therapy, recombinant TRAIL treatment, TRAIL receptor agonists) as a strategy to improve metabolic risk factors in diabetic patients, especially considering the acceptable safety profile demonstrated in clinical trials testing TRAIL in cancer patients, caution is warranted in the extrapolation of animal and in vitro data to the clinical setting.